Xencor’s (XNCR) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Xencor (NASDAQ:XNCR) in a research note published on Tuesday, MarketBeat reports. They currently have a $13.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $18.00.

A number of other equities research analysts have also weighed in on XNCR. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Truist Financial assumed coverage on shares of Xencor in a research note on Monday, November 24th. They set a “buy” rating and a $29.00 price target on the stock. Barclays raised their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Finally, Wall Street Zen lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.38.

Xencor Price Performance

NASDAQ XNCR opened at $12.31 on Tuesday. The firm’s fifty day simple moving average is $12.09 and its two-hundred day simple moving average is $13.31. The firm has a market capitalization of $902.80 million, a P/E ratio of -9.93 and a beta of 0.95. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. Xencor has a 12-month low of $6.92 and a 12-month high of $18.69.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. During the same quarter last year, the firm earned ($0.62) EPS. The business’s quarterly revenue was down 46.6% on a year-over-year basis. Analysts forecast that Xencor will post -3.68 EPS for the current fiscal year.

Insider Buying and Selling at Xencor

In other news, VP John R. Desjarlais sold 4,118 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $46,327.50. Following the sale, the vice president directly owned 266,333 shares in the company, valued at $2,996,246.25. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bassil I. Dahiyat sold 14,870 shares of Xencor stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total value of $167,287.50. Following the completion of the transaction, the chief executive officer owned 552,922 shares of the company’s stock, valued at approximately $6,220,372.50. This represents a 2.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 44,020 shares of company stock valued at $499,817. Corporate insiders own 4.76% of the company’s stock.

Institutional Trading of Xencor

Institutional investors have recently bought and sold shares of the business. Hantz Financial Services Inc. grew its stake in Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 2,156 shares during the period. GAMMA Investing LLC increased its holdings in Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC acquired a new position in Xencor during the third quarter worth $44,000. Tower Research Capital LLC TRC raised its position in Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 3,018 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in Xencor by 114.3% during the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 2,105 shares in the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.